
MORE GAINS AHEAD – 63% GAIN ON THIS SUPPLIER OF A KEY COMPONENT FOR VACCINE
Maravai LifeSciences (MRVI) is long from $25.84. MRVI is trading at $42.25 as of this writing. This represents a gain of 63% in a short time. MRVI reported earnings significantly better than the consensus. We have previously written that the target zone was likely to be raised. MRVI supplies a key component of the coronavirus vaccine produced by Pfizer (PFE) and BioNTech (BNTX). The vaccine should provide a sharp increase in revenue. The company also has a diversified product portfolio. Zones For those following the Good Way, the Buy Now rating is ‘NO.’ For those following the Best Way the buy